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Summary
Background: Nasopharyngeal carcinoma is a
rare tumor entity in Switzerland. In contrast, it is
endemic in Asian and African countries. Retro-
spective studies have been conducted in order to
identify risk factors and prognostic determinants
of nasopharyngeal carcinoma. Nonetheless, these
trials were mostly conducted in regions with high
prevalence for the disease and little is known
about the risk factors and prognosis of nasopha-
ryngeal carcinoma for a non-endemic population
inWestern Europe.
Methods: This retrospective trial was con-
ducted to identify risk factors and prognostic de-
terminants of nasopharyngeal carcinoma for a
non-endemic population in Switzerland.
Results: Overall survival was 91%, 77% and
58% for one, three and five years, respectively.
Factors with favourable prognostic value were
concomitant radiochemotherapy regimens, pho-
ton radiotherapy, and a delay between diagnosis
and first therapy session of less than ten weeks, re-
spectively. Factors with unfavourable prognostic
values were age over 65 years at time of diagnosis
and nasopharyngeal carcinoma ofWHO type I.
Conclusion: Risk factors, biological behaviour
and survival are well comparable between endemic
and non-endemic populations for nasopharyngeal
carcinoma. Nonetheless, an aggressive diagnostic
procedure and sophisticated interdisciplinary
therapy are indispensable in order to achieve fa-
vourable outcome. Therefore, diagnosis and ther-
apy of nasopharyngeal carcinoma in non-endemic
populations should be limited to highly special-
ized tertiary centres.
Key words: nasopharyngeal carcinoma, non-en-
demic, prognostic factors, single-institution, survival
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Introduction
Nasopharyngeal carcinoma (NPC), formerly
known as Schmincke-carcinoma, is an uncommon
tumor entity in Switzerland, and its age-adjusted
incidence for both sexes is less than one per
100000 per population and year. However, NPC
occurs more often in Southern China and Africa
with an incidence of 30–50 per 100000 per popu-
lation and year [1–5]. The reason for these geo-
graphical differences are not entirely known, but
genetic susceptibility, ethnical background, and
environmental factors are believed to play a key
role in the cause and progression of the disease [6].
Furthermore, it is evident that the Epstein-Barr
virus (EBV) plays a strong causal role in the patho-
genesis of NPC [6].
The location of NPC and its relationship with
many delicate structures makes a complete surgi-
cal excision quite difficult. Furthermore, NPC is
highly radiosensitive, and therefore, primary radio-
therapy is the gold standard treatment for NPC
with local control rates of 80% and 5-year survival
rates of 70% [7, 8]. Due to the location of the tu-
mor at the skull-base, fragile anatomical structures
can be affected by radiotherapy, such as the brain
stem, spinal cord, temporal lobes, eyes,middle and
inner ears and parotid glands. Recently, intensity
modulated radiotherapy (IMRT) seems to im-
prove tumor coverage and less adverse effects than
with conventional techniques are described [9,
10]. Several studies have reported the advantage of
chemotherapy in combination with radiotherapy
for advanced or metastatic NPC, in comparison
with radiotherapy alone. The best regimen for
combined chemo- and radiotherapeutic treat-
ment, for example neoadjuvant, concurrent, adju-
vant or, a combination of these, is still under inves-
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tigation [11–17]. In T2b or more lesions and/or
N-positive necks, concomitant chemoradiation is
the standard. Furthermore, the disease seems to be
diagnosed mainly at later stages with a cervical
mass being the first clinical sign. Therefore, pa-
tients suffering from NPC should be investigated
with aggressive diagnostic procedures, as patients
with a short delay between diagnosis and treat-
ment have a favourable outcome over patients
with a delayed onset of therapy [18].
A large body of literature has been devoted to
the elucidation of risk factors and prognosis of
NPC [3, 19–22]. Nonetheless, most trials have
been conducted in Asian and African populations
where NPC is endemic. It is therefore not surpris-
ing, that most epidemiological and clinical data is
available for patients from these endemic sites and
the USA, where a lot of first-generation Chinese
immigrants live.
The aim of this retrospective study was to
characterize patients treated for NPC in a single
institution in Switzerland and to identify impor-
tant prognostic factors with an impact on overall
survival for this non-endemic population.
Material and methods
Population and characteristics
Between 1990 and 2005, 34 patients with histologi-
cally proven NPC were treated at the Department of
Otolaryngology, Oncology and Radio-Oncology at the
Kantonsspital Lucerne, a tertiary hospital in Switzerland.
This review was done in accordance to the guidelines of
the local ethics committee.
From the total of 34 patients, 29 (85.3%) were Cau-
casians, three (8.8%) were North Africans, and two were
originally from Asia (5.9%). All the patients were Swiss
citizens.
Clinical and pathological workup
Workup included a full head and neck examination,
routine blood chemistries, a flexible fiberoptic endoscopy
and a computer-assisted tomography (CT), or in case of
bone erosion a supplementary magnetic resonance imag-
ing (MRI). Symptoms at the stage of presentation in-
cluded ear involvement (e.g. otalgia, unilateral serous oti-
tis media), an enlarging neck mass, epistaxis or nasal con-
gestion. Histological diagnosis was performed from
biopsy material of the primary site of the tumor and/or
nodal excision tissue.
NPC was classified according to following World
Health Oranisation (WHO) types: type I for keratinizing
differentiated carcinoma, type II for non-keratinizing car-
cinoma, and type III for undifferentiated carcinoma. The
distribution of the different histological subtypes in the
current study is shown in table 1. All patients were staged
according to the TNM- and the UICC 2002 staging sys-
Table 1
Distribution of
histopathological
types according to
WHO classiﬁcation.
n = %
WHO type I 6 18%
WHO type II 4 12%
WHO type III 24 70%
Table 2
Distribution ofT- and
N-stage according to
TNM classiﬁcation.
N0 N1 N2 N3 Total
Tis 0 0 0 0 0
T1 4 3 0 0 7
T2 2 3 3 0 8
T3 2 0 8 0 10
T4 5 0 4 0 9
Total 13 6 15 0 34
Table 3
Distribution ofTumor
stages according
to UICC 2002
classiﬁcation and
status of patients.
Status
alive
n =
dead
n =
censored
n =
Total
n =
UICC 2002
Stage 0 0 0 0 0
Stage I 3 1 0 4
Stage IIA 1 1 0 2
Stage IIB 5 0 1 6
Stage III 4 6 3 13
Stage IVa 5 3 1 9
Stage IVb 0 0 0 0
Total 18 11 5 34
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tem [23, 24].TheT- andN-Stage and the UICC 2002-tu-
mor stages of the study population are shown in table
2 and 3.
Radiotherapy and chemotherapy
All patients received megavoltage radiation therapy.
From 1990–1998, an adjuvant chemotherapy with cispla-
tin was offered. After 1998, all patients received a concur-
rent radiochemotherapy using cisplatin 100 mg/m
2
i.v. on
day 1, 22, and 43.
With regard to radiotherapy, there was a change in
the treatment technique: The first group was recorded
between 1990 and 1998, the second group between 1998
and 2005. In the first period, the primary tumor and ante-
rior neck were treated with strictly opposing photon fields
(6 MV) up to a dose of 45 Gy, the posterior neck with a
mixture of photons and electrons up to 9 Gy. The upper
mediastinum was treated with anterior fields, blocking the
spinal cord before 45 Gy. In the second period, a strictly
3-D planning was done with up to 8 photon fields (medi-
astinum included) and doses up to 50 Gy for the spinal
cord, covering non-involved neck lymphatic with 54–56
Gy and involved lymphatic up to 60 Gy (or more) and the
primary tumor up to 70–72 Gy (5–6 x2 Gy per week).
Feeding tubes were routinely used during radiation in the
second treatment period.
Follow-up and statistical analysis
All patients were followed for a minimum of three
years after completion of radiation therapy. After treat-
ment, the patients were followed bimonthly for the first
year, quarterly for the second year, and biannually there-
after.
Overall survival rates were analyzed in relation to
various patient and tumor characteristics. Patients in
whom loco-regional control was not achieved at their first
follow-up visit were considered as failures. Patients who
died without evidence of loco-regional or distant disease
were censored at the date of death.
Statistical analysis was carried out using SPSS 14.0
for Windows. Statistical comparisons were made using
Mann-Whitney test for two independent variables. Chi-
square test was applied where appropriate.The method of
Kaplan and Meier was used to plot outcome. Survival
analyses were performed using generalizedWilcoxon test
(Gehan method). A p-value of less than .05 was consid-
ered to be statistically significant.
Results
Patients
Between 1990 and 2005, a total number of 34
patients (24 males, 10 females; sex ratio of 2.4:1
(p <0.05)) were evaluated for a previously un-
treated NPC.The mean age of the patients at the
time of diagnosis was 54.4 years (range 20.2–84.1
years).
Histological assessment
The most prevalentWHO histology type was
type III (n = 24, 71%), followed by WHO type I
(n = 6, 18%) and WHO type II (n = 4, 11%)
(p <0.001).
Staging
The most prevalent T-stage was T3 (n = 10,
29%). Nodal staging was performed by clinical
examination and imaging (CT or MRI). A total of
21 (62%) patients presented with positive neck
nodes. The most prevalent N-stage was N2
(n = 15, 44%). The most prevalent tumor stage,
according to UICC 2002, was stage III (n = 13,
38%).
Follow-up
The median follow-up time among the 18 liv-
ing patients was 3.72 years (range: 1.05–11.51
years). Five patients were discarded due to loss of
follow-up.The median follow-up time among five
censored patients was 2.70 years (range: 0.54–
10.24 years). 14 patients of the latter group
(77.8%) had a minimum of 2-year follow-up, six
(33.3%) had at least 5 years of follow-up, and two
(11.1%) had more than 10 years of follow-up.
Survival rates
For the entire population, the 1-, 3- and
5-year overall survival rates were 91%, 77% and
58%, respectively (fig. 1).A total of eleven patients
died during the observation period. Seven of these
patients died of nasopharyngeal cancer, four pa-
tients died of intercurrent diseases. Deaths due to
secondary primaries or therapy complications
were not reported. Overall, 18 patients are alive
Figure 1
Overall survival.
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Disease-free survival.
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and disease-free at the end of the study period.
Five patients were discarded due to loss of follow-
up.
The actuarial tumor control rates for the
whole series were 81%, 71%, and 71% at 1-, 3-,
and 5 years, respectively (fig. 2). A total of ten pa-
tients suffered from tumor recurrence with a me-
dian time to recurrence of 0.73 years (0.00–9.23
Impact of different parameters on survival
Figure 3
Therapy regiment.
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Figure 4
RT regiment.
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Figure 5
Time to treatment.
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years). Eight of these failures presented as con-
comitant local, neck and distant failure, one pa-
tient presented with isolated local failure and one
with isolated neck failure. Three of these failures
appeared within one year of therapy and nine
within three years. One patient suffered from dis-
tant recurrence after more than five years of fol-
low-up.
Chemotherapy
The form of combined radiochemotherapy
regimen was found to be a strong determinant for
survival: During the years 1998–2005, all 17 pa-
tients had a performance status that allowed con-
comitant radiochemotherapy, whereas during
1990–1998 five patients were treated with sequen-
tial radiochemotherapy (adjuvant chemotherapy)
and 12 patients with radiotherapy only (six pa-
tients with T1/2 N0 lesions, and six patients with
a bad performance status).The survival rates at 1-,
3- and 5 years were 100%, 94% and 73% and
100%, 50% and 50%, and 74%, 64%, and 38%
for concomitant radiochemotherapy, sequential
radio-chemotherapy, and radiotherapy alone, re-
spectively (p <0.05 for concomitant radiochemo-
therapy vs radiotherapy alone in pair wise compar-
ison) (fig. 3).
Radiotherapy
The form of the radiotherapy regimen was
also found to be a determinant for survival: 17 pa-
tients received radiotherapy treatment before
1998 compared to 17 patients with radiotherapy
treatment after 1998.Analysis of deaths in the two
groups revealed a higher proportion of events in
the group treated before 1998 (8 events compared
to 3 events, p <0.05). The survival rates at 1-, 3-
and 5 years were 81%, 61% and 45% for treat-
ment before 1998, compared to 100%, 93%, and
70% for treatment after 1998 (p = 0.058) (fig. 4).
Time to treatment
30 patients (81%) received the first therapy
session within ten weeks after diagnosis with a sur-
vival rate of 93%, 85%, and 62% at 1-, 3- and
5 years compared to four patients (12%) where
treatment was delayed by more than ten weeks
after diagnosis with survival rates of 75%, 25%,
and 25% at 1-, 3- and 5 years (p <0.05) (fig. 5).
WHO histology type
The WHO histology type of the tumor was
another strong determinant for survival. The sur-
vival rates at 1- and 3 years were 50% and 33%,
and 100% and 71%, as well as 100% and 84% for
tumors of WHO type I, II and III, respectively.
(5-year survival rates were not available due to
short follow-up period in the group of WHO
type II). Pairwise comparison revealed significant
differences in survival rates between type I and III
(p <0.05) (fig. 6).
Age
The patient’s age group at the time of diagno-
sis (<45 years, n = 10; 45–65 years, n = 13; >65
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years, n = 11) was found to be further determinant
for survival. The survival rates at 1- and 3 years
were 100% and 100%, and 100% and 84%, as well
as 71% and 43% for patients less than 45 years, 45
to 65 years and patients over 65 years, respectively
(5-year survival rates were not available due to
short follow-up period in the latter group). Sur-
vival rates were significantly decreased in the age
group older than 65 years in pairwise comparison
with the group younger than 45 years at diagnosis
(p = 0.006), and the group 45–65 years (p = 0.023),
respectively (fig. 7). Survival rates were equal in
both male and female patients suffering from
NPC. Survival rates were 96%, 74%, and 59% for
males, and 80%, 80%, and 55% for females for 1-,
3- and 5-year overall survival, respectively.
TN-stage
In order to compare the results with those of
other published series, integrated T- and N-stage
categories were used [25, 26]. Patients in these
groups were further characterized as to the ab-
sence (N0) or presence (N+) of cervical metastases
at time of treatment. Three-year overall survival
rates for the mentioned groups were 83%, 83%,
86% and 60% for the groups T1–2 N0,T1–2 N+,
T3–4 N0, T3–4 N+, respectively.
Figure 6
WHO type.
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Figure 7
Age groups.
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Discussion
NPC is a unique entity in head and neck ma-
lignancies: its sensitivity to radiotherapy and
chemotherapy and its survival characteristics
render the disease inimitable. Most of the literate
arises from Asia, as described previously. In the
current work, we describe important prognostic
factors for patients suffering from NPC in a non-
endemic region.The limitation of this work is the
small sample size and its retrospective character,
however, the study population was found to be
representative in means of age, sex, histology type,
and tumor stage compared to other epidemiologi-
cal reports for NPC in high-prelevance regions
such as Asia and Africa. Furthermore, recurrence
rates and survival after standard treatment in our
series was comparable with reports from endemic
sites, indicating that NPC at non-endemic sites
share similar biological features compared to the
better understood disease from endemic regions
[5, 21, 26].
We were able to clearly identify important
prognostic factors for NPC in this single-institu-
tional treated cohort. Factors for unfavourable
prognostic behaviour were increased age at time
of diagnosis, advancedTN-stage and NPCWHO
type I. The latter finding correlates with the re-
sults found in a European study featuring ten
countries and involving 2.054 patients: the overall
5-year survival rates for differentiated and undif-
ferentiated were 40 and 50%, respectively [27].
Venkitaraman R [28] found that poorly differenti-
ated carcinoma (WHO type III) fared significantly
better than carcinoma with squamous histology
(WHO type I and II), with 5-year disease-free sur-
vival of 56% and 44%, respectively. In our work,
the disease was diagnosed at later stages, with a
cervical mass being the most common presenta-
tion. This is in correlation with the findings of
d’EspineyAmaro C et al. [29].Other unfavourable
prognostic factors, such as a poor performance
status [30], different genetic mutations [31] were
not analyzed due to the retrospective character of
this study.
On the contrary, important prognostic factors
for favourable prognosis were identified: a short
interval between time of diagnosis and onset of ra-
diotherapy was found to be a strong and important
determinant for survival.This correlates with pre-
vious work from Kwong DL et al. [18] for an en-
demic population and highlights the urgency for
aggressive diagnosis and sophisticated therapy at
highly specialized institutions. In this work, pa-
tients with delayed time to treatment were statis-
tically not significantly suffering from advanced
disease compared to the other group. Further-
more, photon radiotherapy regiments with strict
3-D plans were found to be strongly superior over
older radiation regiments. The dose distribution
of modern photon radiotherapy regiments is much
more homogeneous, especially in the posterior
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deep part of the neck and allows higher total dose
in primary tumour region and/or neck nodes.
Therefore, the total dose in macroscopic tumor
regions could be increased to nearly 70 Gy, with-
out experiencing increased complication rates of
neurological late toxicity of the spinal cord. Re-
cent studies show improved tumor coverage and
spared normal tissues by using IMRT instead of
conventional techniques [9, 10]. In our study, the
use of concomitant chemotherapy showed signifi-
cantly better survival rates than sequential chemo-
radiotherapy or radiotherapy alone.Other authors
have also reported the same results [32, 33]. How-
ever, in our series, the benefit for survival in figure
3 was twofold: Firstly, new imaging technologies
render a better definition of the lesion in the
group treated during 1998–2005 compared to the
older group. The primary is optimally assessed
with CT andMR imaging for staging. Intracranial
invasion should particularly be assessed with con-
trast MR imaging. Recent studies advocate PET/
CT and head-and-neck MRI as initial radio-
graphic workup [34]. Secondly, and even more im-
portant, patients in the group 1998–2005 were
given a total dose of 70 Gy to the primary, whereas
the patients within the group 1990–98 were only
given a total dose of 45 Gy. A dose of 70–72 Gy to
the primary tumor and metastatic lymph nodes
seems to be widely accepted. In case of residual
primary lesion, a boost dose of 8–24 Gy will be
added [35]. However, higher radiation doses con-
tribute to a higher incidence of radiation-related
complications.Whether chemotherapy should be
performed by using cisplatin only, or in combina-
tion with another agent, since it shows good cura-
tive results and less adverse effects, remains un-
clear. It is evident that concurrent chemotherapy
increases the morbidities, such as grade 3–4 hema-
tologic and mucosal toxicities [28]. The role of
EBV-associated with NPC is manifold: there are
geographical variations in the prevalence of EBV-
associated NPC. There is an intermediate risk of
NPC in southern France where a lot of migrants
of Maghrebian origin live, while the risk of NPC
is low in Northern Europe, such as Scandinavia
[36]. The positive role of EBV associated with in-
creased survival [37] was not further analyzed in
our small samples size due to its retrospective
character.
Conclusion
In conclusion, we identified important prog-
nostic factors in terms of survival in a small patient
population suffering fromNPC treated in a single
institution in a non-endemic site. Risk factors, bi-
ological behaviour and survival are comparable
between endemic and non-endemic populations
for NPC. Nonetheless, aggressive diagnostic pro-
cedures and sophisticated interdisciplinary ther-
apy regimes performed by experienced otorhi-
nolaryngologists, oncologists and radiooncolo-
gists are absolutely mandatory in order to achieve
favourable outcome. Therefore, we suggest that
diagnosis and therapy of NPC in non-endemic
populations should be limited to highly special-
ized tertiary centres.
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